The research team around Prof. Dr. Christian Splieth (Preventive Dentistry & Paediatric Dentistry, University of Greifswald, Germany) will present the results of the clinical study on the treatment of occlusal caries with CURODONT™ REPAIR and Duraphat® (22’600 ppm Fluoride) or Duraphat® alone at this year’s ORCA conference. The study results show clear superiority of the combinational therapy of Curodont™Repair and Fluoride compared to the treatment with the gold-standard fluoride alone. In the test group more than twice as many caries lesions were inactivated (OR 7.6; p=0.0006) and the values given by the caries diagnostic Diagnodent® showed a clear reduction of the caries related values for the test group (-18.6) and lack of significant change for the control group (-1.1).
The abstract of the blinded, randomised and controlled clinical study was published in the dental journal Caries Research prior to the conference (Caries Res 2015; 49; 297-369; Abstract #30).
Link to the CURODONT Repair webpage
Link to Caries Research
Link to ORCA Conference 2015
About Curodont™ and the Curolox™ Technology
The patented Curolox® Technology is based on peptides self-assembling into a 3-dimensional matrix, triggering biomimetic mineralisation and repair. The core technology is the basis for all innovative credentis products.
CURODONT™ REPAIR provides dentists with a non-invasive option for natural in-depth mineralisation which allows the regeneration of caries lesions and similar defects. Applied to an early lesion, CURODONT™ REPAIR forms a scaffold within the lesion to guide new hydroxyapatite (tooth mineral) crystals to form and grow. Ideally, the caries is stopped and the lesion will mineralise within several weeks.
CURODONT™ PROTECT uses the Curolox® Technology to protect the tooth surface from acid attack.
CURODONT™ D’SENZ is optimised for the treatment of dentine hypersensitivity, to be used before dental hygiene treatment or in conjunction with tooth bleaching.
With its regenerative product line, credentis supports the trend towards prevention and early treatment. The ultimate goal is to prevent caries through the use of its regenerative solutions and frequent recalls by dentists and hygienists.
About credentis ag
credentis ag is headquartered in the Technopark Aargau, Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Science Foundation (SNSF), Aargauer Forschungsfonds in collaboration with the FHNW School of Life Sciences in Muttenz and the Medical Technologies IKC (in co-operation with the University of Leeds).
Dr. Dominik Lysek, CEO and Michael Hug, CTO have a strong track record in science, development and medical technology, with focus in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz, Gerard Moufflet and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.
Help employers find you! Check out all the jobs and post your resume.
The abstract of the blinded, randomised and controlled clinical study was published in the dental journal Caries Research prior to the conference (Caries Res 2015; 49; 297-369; Abstract #30).
Link to the CURODONT Repair webpage
Link to Caries Research
Link to ORCA Conference 2015
About Curodont™ and the Curolox™ Technology
The patented Curolox® Technology is based on peptides self-assembling into a 3-dimensional matrix, triggering biomimetic mineralisation and repair. The core technology is the basis for all innovative credentis products.
CURODONT™ REPAIR provides dentists with a non-invasive option for natural in-depth mineralisation which allows the regeneration of caries lesions and similar defects. Applied to an early lesion, CURODONT™ REPAIR forms a scaffold within the lesion to guide new hydroxyapatite (tooth mineral) crystals to form and grow. Ideally, the caries is stopped and the lesion will mineralise within several weeks.
CURODONT™ PROTECT uses the Curolox® Technology to protect the tooth surface from acid attack.
CURODONT™ D’SENZ is optimised for the treatment of dentine hypersensitivity, to be used before dental hygiene treatment or in conjunction with tooth bleaching.
With its regenerative product line, credentis supports the trend towards prevention and early treatment. The ultimate goal is to prevent caries through the use of its regenerative solutions and frequent recalls by dentists and hygienists.
About credentis ag
credentis ag is headquartered in the Technopark Aargau, Switzerland. credentis has won multiple awards as well as support from organizations such as Genilem. Public grants include Swiss National Science Foundation (SNSF), Aargauer Forschungsfonds in collaboration with the FHNW School of Life Sciences in Muttenz and the Medical Technologies IKC (in co-operation with the University of Leeds).
Dr. Dominik Lysek, CEO and Michael Hug, CTO have a strong track record in science, development and medical technology, with focus in the dental industry. credentis board members Dr. Werner Berner, Dr. Michael Peetz, Gerard Moufflet and Dr. Erich Platzer (chairman), contribute their pharma, medtech and dental industry expertise.
Help employers find you! Check out all the jobs and post your resume.
